Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 11, 2015, Pages 1716-1723

  Fahrmann, Johannes F ^a   Kim, Kyoungmi ^b   DeFelice, Brian C ^a   Taylor, Sandra L ^b   Gandara, David R ^b   Yoneda, Ken Y ^c   Cooke, David T ^b   Fiehn, Oliver ^a,d   Kelly, Karen ^b   Miyamoto, Suzanne ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; ASPARTIC ACID; CITRULLINE; GLUTAMIC ACID; MALTOSE; MALTOTRIOSE; PYROPHOSPHATE; TRYPTOPHAN; TUMOR MARKER; XYLOSE;

AGED; ARTICLE; BLOOD BIOCHEMISTRY; BLOOD SAMPLING; CANCER CLASSIFICATION; CASE CONTROL STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; GAS CHROMATOGRAPHY; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; TIME OF FLIGHT MASS SPECTROMETRY; ADENOCARCINOMA; BLOOD; LUNG NEOPLASMS; MIDDLE AGED;

ADENOCARCINOMA; AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; METABOLOMICS; MIDDLE AGED;

EID: 84946559080     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-0427     Document Type: Article

References (22)

1. Prevention CfDCa. National Center for Health Statistics. CDC WONDER On-line Database, compiled from Compressed Mortality File 1999-2012. 2014; Series 20 No. 2R.
2. Society AC. Cancer Facts and Figures. 2014:1-60. Available form: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index.
3. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, et al. Twenty-two years of phase III trials for patients with advanced non-small cell lung cancer: sobering results. J Clin Oncol 2001;19:1734-42.
4. Pass HI, Beer DG, Joseph S, Massion P. Biomarkers and molecular testing for early detection, diagnosis, and therapeutic prediction of lung cancer. Thorac Surg Clin 2013;23:211-24.
5. Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL, Massion PP. The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res 2012;5:992-1006.
6. Serkova NJ, Glunde K. Metabolomics of cancer. Methods Mol Biol 2009;520:273-95.
7. Kwon H, Oh S, Jin X, An YJ, Park S. Cancer metabolomics in basic science perspective. Arch Pharm Res 2015;38:372-80.
8. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications ofmetabolomics in oncology: a review. Clin Cancer Res 2009;15:431-40.
9. Claudino WM, Goncalves PH, Di Leo A, Philip PA, Sarkar FH. Metabolomics in cancer: a bench-to-bedside intersection. Crit Rev Oncol Hematol 2012;84:1-7.
10. Scholz M, Fiehn O. SetupX-a public study design database for metabolomic projects. Pac Symp Biocomput 2007;12:169-80.
11. Fiehn O, Wohlgemuth G, Scholz M, Kind T, Lee Do Y, Lu Y, et al. Quality control for plant metabolomics: reporting MSI-compliant studies. Plant J 2008;53:691-704.
12. Fiehn O, Wohlgemuth G, Scholz M. Setup and annotation of metabolomic experiments by integrating biological and mass spectrometric metadata. Data Integration in the Life Sciences, Proceedings 2005;3615:224-39.
13. Taylor SL, Kim K. A jackknife and voting classifier approach to feature selection and classification. Cancer Inform 2011;10:133-47.
14. McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, et al. Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med 2013;11:220.
15. Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE II. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 2007;25:5578-83.
16. Li XJ, Hayward C, Fong PY, Dominguez M, Hunsucker SW, Lee LW, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med 2013;5:207ra142.
17. Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol 2014;32:768-73.
18. Wedge DC, Allwood JW, Dunn W, Vaughan AA, Simpson K, Brown M, et al. Is serum or plasma more appropriate for intersubject comparisons in metabolomic studies? An assessment in patients with small-cell lung cancer. Anal Chem 2011;83:6689-97.
19. Yu Z, Kastenmuller G, He Y, Belcredi P, Moller G, Prehn C, et al. Differences between human plasma and serum metabolite profiles. PLoS ONE 2011;6:e21230.
20. Wikoff W, Grapov D, Fahrmann J, DeFelice B, Rom W, Pass H, et al. Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma. Cancer Prev Res 2015;8:410-8.
21. Mohamed A, Deng X, Khuri FR, Owonikoko TK. Altered glutamine metabolism and therapeutic opportunities for lung cancer. Clin Lung Cancer 2014;15:7-15.
22. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.